journal article·2018-07-11

Nanoscale Melittin@Zeolitic Imidazolate Frameworks for Enhanced Anticancer Activity and Mechanism Analysis

Yawei Li, Na Xu, Wenhe Zhu, Lei Wang, Bin Liu, Jianxu Zhang, Zhigang Xie, Wensen Liu

ACS Applied Materials & Interfaces· Volume 10· Issue 27
Publisher page

Abstract

The cytolytic peptide melittin (MLT) is an important candidate of anticancer drug owing to its hemolytic properties. Nevertheless, its clinical applications are severely restricted as a result of its nonspecific toxicities like hemolysis. In this work, we reported MLT-loaded zeolitic imidazolate framework-8 (MLT@ZIF-8) nanoparticles (NPs). The formed MLT@ZIF-8 NPs not only possess excellent stability but also efficiently inhibit the hemolysis bioactivity of MLT. Confocal scanning imaging and cytotoxicity experiments revealed that as-synthesized MLT@ZIF-8 NPs exhibit enhanced cellular uptake and cytotoxicity toward cancer cells compared to MLT. The mechanism is well investigated by a series of transcriptome analysis, which indicates that MLT@ZIF-8 NPs can regulate the expression of 3383 genes, and the PI3K/Akt-regulated p53 pathway is involved in MLT@ZIF-8 NPs induced A549 cells apoptosis. Finally, MLT@ZIF-8 NPs exhibit enhanced antitumor activity than free MLT in vivo, while no obvious systemic toxicity has been found. This work emphasizes the great potential of utilizing MOF as a simple and efficient nanoplatform for deliverying cytolytic peptides in cancer treatment, and also the investigation on the antitumor mechanism could provide theoretical support for clinical usage of MLT.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Healthcare and Venom Research · Antimicrobial Peptides and Activities · Silk-based biomaterials and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, Changchun, 130122, P. R. China

Jilin Medical University, Jilin, 132013, P. R. China

State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China

Funding

China Postdoctoral Science Foundation

References (68)

Show source-provided references
1. 10.1007/s00018-005-4560-210.1007/s00018-005-4560-2 ↗
2. 10.1021/acs.bioconjchem.5b0024610.1021/acs.bioconjchem.5b00246 ↗
3. 10.1016/S0005-2736(02)00403-010.1016/S0005-2736(02)00403-0 ↗
4. 10.1021/nl073290r10.1021/nl073290r ↗
5. 10.1002/wnan.12610.1002/wnan.126 ↗
6. 10.1126/science.177.4046.31410.1126/science.177.4046.314 ↗
7. 10.1016/j.etap.2013.06.00910.1016/j.etap.2013.06.009 ↗
8. 10.1007/s10540-006-9030-z10.1007/s10540-006-9030-z ↗
9. 10.1016/0304-4157(90)90006-X10.1016/0304-4157(90)90006-X ↗
10. 10.1016/j.toxicon.2015.12.00510.1016/j.toxicon.2015.12.005 ↗
11. 10.1002/hep.2224010.1002/hep.22240 ↗
12. 10.1021/ja806287510.1021/ja8062875 ↗
13. 10.1002/smll.20090018610.1002/smll.200900186 ↗
14. 10.1007/s11274-010-0491-710.1007/s11274-010-0491-7 ↗
15. 10.1096/fj.09-15313010.1096/fj.09-153130 ↗
16. 10.1007/s00262-003-0457-910.1007/s00262-003-0457-9 ↗
17. 10.1002/bab.5710.1002/bab.57 ↗
18. 10.1016/S1380-2933(96)00055-310.1016/S1380-2933(96)00055-3 ↗
19. 10.1016/0304-4165(93)90077-L10.1016/0304-4165(93)90077-L ↗
20. 10.1016/j.jconrel.2011.08.02910.1016/j.jconrel.2011.08.029 ↗
21. 10.1021/nn400683s10.1021/nn400683s ↗
22. 10.1021/acs.bioconjchem.6b0067710.1021/acs.bioconjchem.6b00677 ↗
23. 10.1080/0363904090271803910.1080/03639040902718039 ↗
24. 10.1039/C6TB00952B10.1039/C6TB00952B ↗
25. 10.1021/acsami.7b0643110.1021/acsami.7b06431 ↗
26. 10.1021/am300098410.1021/am3000984 ↗
27. 10.1021/acsami.6b0335510.1021/acsami.6b03355 ↗
28. 10.1016/j.ejps.2016.12.02110.1016/j.ejps.2016.12.021 ↗
29. 10.1016/j.bbamem.2006.05.01610.1016/j.bbamem.2006.05.016 ↗
30. 10.1126/science.123044410.1126/science.1230444 ↗
31. 10.1021/acs.chemmater.7b0022810.1021/acs.chemmater.7b00228 ↗
32. 10.1021/acsami.6b1415210.1021/acsami.6b14152 ↗
33. 10.1002/adfm.20080113010.1002/adfm.200801130 ↗
34. 10.1021/acsami.5b0431510.1021/acsami.5b04315 ↗
35. 10.1002/adfm.20160546510.1002/adfm.201605465 ↗
36. 10.1002/adfm.20160321210.1002/adfm.201603212 ↗
37. Zhang H. · ACS Appl. Mater. Interfaces · 2017 · 9 · 1968710.1021/acsami.7b05142 ↗
38. 10.1021/acsami.7b1652210.1021/acsami.7b16522 ↗
39. 10.1021/am301365h10.1021/am301365h ↗
40. 10.1021/nn406590q10.1021/nn406590q ↗
41. 10.1021/acsbiomaterials.7b0043510.1021/acsbiomaterials.7b00435 ↗
42. 10.1038/ncomms824010.1038/ncomms8240 ↗
43. 10.1002/adma.20160278210.1002/adma.201602782 ↗
44. 10.1021/acsami.6b0989310.1021/acsami.6b09893 ↗
45. 10.1002/adma.20160443310.1002/adma.201604433 ↗
46. 10.1039/c0cc05002d10.1039/c0cc05002d ↗
47. 10.1039/C7CE00022G10.1039/C7CE00022G ↗
48. 10.1021/acsnano.6b0499610.1021/acsnano.6b04996 ↗
49. 10.1016/j.vaccine.2013.11.06910.1016/j.vaccine.2013.11.069 ↗
50. 10.1039/C6CC09280B10.1039/C6CC09280B ↗
51. 10.1002/hep.2224010.1002/hep.22240 ↗
52. 10.1021/ja806287510.1021/ja8062875 ↗
53. 10.1039/C3TB20832J10.1039/C3TB20832J ↗
54. 10.1080/0192623070132033710.1080/01926230701320337 ↗
55. 10.1001/archsurg.133.7.77310.1001/archsurg.133.7.773 ↗
56. 10.1080/0049825090313799010.1080/00498250903137990 ↗
57. 10.1038/sj.embor.740019110.1038/sj.embor.7400191 ↗
58. Watson C. J. · Breast Cancer Res. · 2006 · 8 · 110.1186/bcr1401 ↗
59. 10.1038/ncomms1136310.1038/ncomms11363 ↗
60. 10.4238/2015.November.18.5410.4238/2015.November.18.54 ↗
61. 10.1186/1471-2164-12-55110.1186/1471-2164-12-551 ↗
62. 10.1038/srep1740910.1038/srep17409 ↗
63. 10.1038/nrc.2016.1510.1038/nrc.2016.15 ↗
64. Brambilla E. · Am. J. Pathol. · 1996 · 149 · 1941
65. 10.3892/etm.2016.328210.3892/etm.2016.3282 ↗
66. 10.1038/sj.leu.240282410.1038/sj.leu.2402824 ↗
67. 10.1007/s13277-015-3815-210.1007/s13277-015-3815-2 ↗
68. 10.1158/0008-5472.CAN-16-209810.1158/0008-5472.CAN-16-2098 ↗